used GNE-493 to reveal a new therapeutic target for prostate cancer by blocking the PI3K-AKT-mTOR pathway and inducing ROS production which brought about oxidative damage and necroptosis in prostate cancer cells (202). Here, MTOR is linked to prostate carcinoma.